| HOME >> BIOLOGY >> TECHNOLOGY |
Basic and
diluted loss
per common
share $ (0.57) $ (0.59) $ (0.47)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted
average
number of
common
shares
outstanding 55,804,674 43,755,160 34,046,450
Excludes
common shares
held in
escrow for
contingent
additional
payment
related to
the
acquisition
of Delex
Therapeutics
Inc. 2,380,953 2,380,953 2,777,778
-------------------------------------------------------------------------
-------------------------------------------------------------------------
YM BIOSCIENCES INC.
(A DEVELOPMENT STAGE COMPANY)
Consolidated Statements of Cash Flows
(Amounts in Canadian dollars, unless otherwise noted)
-------------------------------------------------------------------------
Period from
inception on
August 17,
1994
Years ended June 30, to June 30,
2007 2006 2005 2007
-------------------------------------------------------------------------
Cash provided
by (used in):
Operating
activities:
Loss for the
period $ (31,730,240) $ (25,814,607) $ (15,859,295) $(117,506,608)
Items not
involving
cash:
Deprecia-
tion of
property
and
equipment 107,
'/>"/>
| SOURCE YM BioSciences Inc. Copyright©2007 PR Newswire. All rights reserved |